SAME-DAY TRIPLE THERAPY WITH PHOTODYNAMIC THERAPY, INTRAVITREAL DEXAMETHASONE, AND BEVACIZUMAB IN WET AGE-RELATED MACULAR DEGENERATION

被引:28
作者
Bakri, Sophie J. [1 ]
Couch, Steven M. [1 ]
McCannel, Colin A. [1 ]
Edwards, Albert O. [1 ]
机构
[1] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2009年 / 29卷 / 05期
关键词
age-related macular degeneration; choroidal neovascularization; bevacizumab; photodynamic therapy; dexamethasone; triple therapy; steroid; anti-VEGF; verteporfin; avastin; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; INJECTION; PHARMACOKINETICS; TRIAMCINOLONE; RANIBIZUMAB; COMBINATION; AVASTIN; REGIMEN; PDT;
D O I
10.1097/IAE.0b013e3181a46a8a
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report the results of same-day triple therapy with reduced fluence photodynamic therapy, intravitreal dexamethasone, and bevacizumab in patients with neovascular age-related macular degeneration. Methods: Retrospective case series. Records of patients who received same-day triple therapy with reduced fluence photodynamic therapy (25 J/cm(2)), intravitreal dexamethasone (200 mu g), and intravitreal bevacizumab (1.25 mg) were reviewed. All patients had neovascular subfoveal age-related macular degeneration with at least 1 year of follow-up. Snellen visual acuity (VA), central macular thickness on optical coherence tomography, intraocular pressure, and endophthalmitis occurrence were recorded. Results: The 31 patients were observed for a mean of 13.7 months. In all patients, mean baseline VA was 20/80 and vision at final follow-up was 20/60 (P = 0.69). In patients who received previous treatment for exudative age-related macular degeneration In = 18), mean baseline VA was 201100 and vision at final follow-up (mean, 13.7 months) was 20/100 (P = 0.31). In treatment-naive patients (n = 13), mean baseline VA was 20/60 and vision at final follow-up (mean, 13.5 months) was 20/40 (P = 0.31). In all patients, mean central macular thickness was 293 mu m at baseline and 245 mu m at final follow-up (P = 0.053). In previously treated patients (n = 18), mean central macular thickness was 325 mu m at baseline and 265 [mu m at final follow-up (P = 0.10). In treatment-naive patients, mean central macular thickness was 249 mu m at baseline (n = 13) and 218 mu m at final follow-up (P = 0.34). Previously treated patients required more antivascular endothelial growth factor injections (mean = 3.6) than treatment-naive patients (mean = 0.8), but the mean number of repeat triple therapy treatments was 0.3 in both groups. Changes in intraocular pressure and endophthalmitis were not observed during follow-up. Conclusion: Same-day triple therapy maintained VA and decreased macular thickness in patients with and without previous antivascular endothelial growth factor therapy. Triple therapy may reduce the number of antivascular endothelial growth factor injections in some patients and stabilize vision in some patients not responding to antivascular endothelial growth factor therapy. RETINA 29:573-578, 2009
引用
收藏
页码:573 / 578
页数:6
相关论文
共 23 条
[1]   Triple therapy for choroidal neovascularization due to agerelated macular degeneration - Verteporfin PDT, bevacimmab, and dexamethasone [J].
Augustin, Albert J. ;
Puls, Stephan ;
Offermann, Indre .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (02) :133-140
[2]   Pharmacokinetics of intravitreal ranibizumab (Lucentis) [J].
Bakri, Sophie J. ;
Snyder, Melissa R. ;
Reid, Joel M. ;
Pulido, Jose S. ;
Ezzat, Mohamed K. ;
Singh, Ravinder J. .
OPHTHALMOLOGY, 2007, 114 (12) :2179-2182
[3]   Pharmacokinetics of intravitreal bevackumab (avastin) [J].
Bakri, Sophie J. ;
Snyder, Melissa R. ;
Reid, Joel M. ;
Pulido, Jose S. ;
Singh, Ravinder J. .
OPHTHALMOLOGY, 2007, 114 (05) :855-859
[4]   Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection [J].
Beer, PM ;
Bakri, SJ ;
Singh, RJ ;
Liu, WG ;
Peters, GB ;
Miller, M .
OPHTHALMOLOGY, 2003, 110 (04) :681-686
[5]  
Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
[6]   Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[7]  
Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
[8]   Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors [J].
Henderson, BW ;
Gollnick, SO ;
Snyder, JW ;
Busch, TM ;
Kousis, PC ;
Cheney, RT ;
Morgan, J .
CANCER RESEARCH, 2004, 64 (06) :2120-2126
[9]   Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid [J].
Kim, IK ;
Husain, D ;
Michaud, N ;
Connolly, E ;
Lane, AM ;
Durrani, K ;
Hafezi-Moghadam, A ;
Gragoudas, ES ;
O'Neill, CA ;
Beyer, JC ;
Miller, JW .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (01) :357-363
[10]  
Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929